摘要
目的:系统评价国内萘丁美酮治疗类风湿关节炎的临床疗效和安全性。方法:对有关萘丁美酮治疗类风湿关节炎的疗效和不良反应研究文献进行Meta分析。结果:共有9项研究符合纳入标准。萘丁美酮治疗类风湿关节炎疗效总体优于对照组[RR=1.11,95%C(I1.02,1.20),P=0.01],不良反应发生率低于对照组[RR=0.71,95%C(I0.41,1.22),P=0.007]。结论:现有研究显示,萘丁美酮治疗类风湿关节炎疗效优于对照组,且安全性较高。但由于本研究中纳入文献在质量及数量上的局限,上述结论尚需大样本、长期随访的高质量随机对照试验进一步证实。
OBJECTIVE: To evaluate the clinical curative effect and safety of nabumetone for rheumatoid arthritis. METHODS: The researches about the study on the curative effect and ADRs of nabumetone for rheumatoid arthritis were retrieved and cartied out by Meta-analysis. RESULTS: 9 researches were up to the including criteria. As compared with the control group, nabumetone has better effect [RR=1.11,95% CI(1.02, 1.20), P=0.01] but fewer ADRs [RR=0.71,95% CI(0.41, 1.22), P=0.007] in clinical treatment of rheumatoid arthritis. CONCLUSION: The evidence currently available shows that nabumetone has better efficacy and safety. Because the RCTs available for this systematic review are too small, more and further high-quality large-scale RCTs with long-term follow up are required to provide more reliable evidence
出处
《中国药房》
CAS
CSCD
北大核心
2010年第12期1110-1112,共3页
China Pharmacy